NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SENORES · data 2026-10-30
Senores Pharmaceuticals Ltd.
In plain words
Price: 29.1% below its 52-week high of ₹1,599.
Delivery: 43.5% of traded shares were kept for delivery over the last 10 sessions, against 45.0% over the last 60.
Latest results: a net profit of ₹39 cr for the quarter ended Sept 2026 (+22.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹722 cr |
| Net profit (last 12 months) | ₹133 cr |
| Sales growth, 3 years (yearly) | 161.6% |
| Profit growth, 3 years (yearly) | 139.2% |
Latest results in brief (Q2 FY27)
SENORES Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹192.33 crore, up 18.9% YoY and up 6.7% QoQ.
Net profit was ₹39.49 crore, up 22% YoY and up 28.6% QoQ.
Operating margin was 30% (30.6% a year ago).
EPS was ₹8.85, up 35.3% YoY and up 33.9% QoQ.
SENORES के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹192.33 करोड़; पिछले साल की तुलना में 18.9% की बढ़त, पिछली तिमाही की तुलना में 6.7% की बढ़त।
शुद्ध मुनाफ़ा: ₹39.49 करोड़; पिछले साल की तुलना में 22% की बढ़त, पिछली तिमाही की तुलना में 28.6% की बढ़त।
ऑपरेटिंग मार्जिन: 30% (एक साल पहले 30.6%)।
EPS: ₹8.85; पिछले साल की तुलना में 35.3% की बढ़त, पिछली तिमाही की तुलना में 33.9% की बढ़त।
SENORESના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹192.33 કરોડ; ગયા વર્ષની સરખામણીએ 18.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 6.7% વધારો.
ચોખ્ખો નફો: ₹39.49 કરોડ; ગયા વર્ષની સરખામણીએ 22% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 28.6% વધારો.
ઓપરેટિંગ માર્જિન: 30% (એક વર્ષ પહેલાં 30.6%).
EPS: ₹8.85; ગયા વર્ષની સરખામણીએ 35.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 33.9% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
17/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 40.6% over the last 20 sessions vs 46.0% in the 40 before (0.88x); shares delivered per day 1.34x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Insider
- 29 Oct 26Results Q2 FY27 results: profit +22.0% YoY -14.4% next session
- 17 Aug 26Insider SAST disclosure: Ashokkumar Vijaysinh Barot +1 acquired 30,000 shares +4.0% next session
- 27 Jul 26Results Q1 FY27 results: profit +55.7% YoY -4.6% next session
- 27 May 26Results Q4 FY26 results: profit +104.1% YoY -3.0% next session
- 20 Jan 26Results Q3 FY26 results: profit +84.3% YoY +3.6% next session
- 6 Nov 25Results Q2 FY26 results: net profit ₹32.4 cr +7.3% next session
- 24 Jul 25Results Q1 FY26 results: net profit ₹19.7 cr +9.9% next session
- 19 May 25Results Q4 FY25 results: net profit ₹18 cr +1.5% next session
- 24 Jan 25Results Q3 FY25 results: net profit ₹17.2 cr -6.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹192 cr | ₹39 cr | +22.0% | 30.0% | 8.85 |
| Jun 2026 | ₹180 cr | ₹31 cr | +55.7% | 29.8% | 6.61 |
| Mar 2026 | ₹175 cr | ₹37 cr | +104.1% | 27.1% | 7.96 |
| Dec 2025 | ₹175 cr | ₹32 cr | +84.3% | 30.9% | 7.29 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 45.82% | 45.82% | 45.82% | 45.80% |
| Foreign institutions (FII) | 6.01% | 6.62% | 3.64% | 3.35% |
| Domestic institutions (DII) | 10.84% | 9.77% | 9.61% | 9.31% |
| Mutual funds | 7.36% | 6.56% | 5.07% | 4.88% |
| Retail investors | 16.21% | 15.47% | 15.32% | 15.13% |
| Number of shareholders | 42,642 | 36,498 | 34,126 | 34,401 |
Common questions
What was Senores Pharmaceuticals Ltd.'s latest quarterly profit?
Senores Pharmaceuticals Ltd. reported a net profit of ₹39 cr for the quarter ended Sept 2026 (+22.0% on the same quarter a year earlier), on revenue of ₹192 cr.
How much do promoters hold in Senores Pharmaceuticals Ltd.?
Promoters held 45.82% of Senores Pharmaceuticals Ltd. at the end of Sept 2026, with 2.81% of promoter shares pledged.
Is Senores Pharmaceuticals Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.37.
What is Senores Pharmaceuticals Ltd.'s P/E ratio?
About 39.2, based on the last 12 months' earnings and a price of ₹1,133.9 (data 2026-10-30).
What is the 52-week high and low of Senores Pharmaceuticals Ltd.?
The 52-week high is ₹1,599 and the 52-week low is ₹706.
Similar companies
FDC Ltd. (FDC) · Innova Captab Limited (INNOVACAP) · Sun Pharma Advanced Research Co. Ltd. (SPARC) · Orchid Pharma Limited (ORCHPHARMA) · RPG Life Sciences Limited (RPGLIFE)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SENORES in NSE Scanner →